MGI Tech DNBSEQ-T7+ genetic sequencer

MGI Tech has announced the DNBSEQ-T7+, its latest high-throughput sequencer. Designed to meet the rising demand for large-scale genomic research, the product delivers more than 14 Tb of data in just 24 h while offering a small footprint of just 1 m², flexible run configurations and end-to-end automation. It combines high daily output with ease of use and multi-omics versatility.

As sequencing becomes increasingly affordable, researchers are demanding instruments that deliver faster results as well as higher throughput, accuracy and quality. That’s why MGI developed the T7+ as a continuation of its T7, designed to deliver greater speed, scalability, flexibility and performance to meet the evolving demands of clinical research, population genomics and large-scale sequencing projects.

The device integrates MGI’s DNBSEQ technology with next-generation fluidics, optics and bioinformatics, creating a platform that is faster, smarter and more versatile than its predecessor. The compact system supports 1–4 flow cells per run, adapts to projects of any scale, and integrates every step — from DNB preparation to bioinformatics analysis — into a fully automated workflow.

Key technical highlights include: throughput of more than 14 Tb/day (vs 7 Tb/day on the T7); annual whole-genome sequencing capacity of up to 35,000 samples; >90% Q40 quality scores, validated in beta testing by leading labs; PE150 reads in under 24 h; 50% lower scanning time with the TDI (Time-Delay Integration) camera; and reduced energy consumption, with over 90% of transport links and certain reagents requiring no cold chain.

By integrating seven-in-one hardware, smartphone-like software and modular-designed consumables, the unit makes sequencing as intuitive as using a smartphone. Its ability to support multi-omics applications — including spatial omics, single-cell, proteomics and methylation — in one run enables concurrent data streams for large cohorts. It enables researchers to sequence 144 human genomes in a single day, accelerating breakthroughs in cancer genomics, rare disease research and precision medicine.